Celgene

Celgene Corporation was a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. Celgene was acquired by Bristol Myers Squibb (BMS) in November 2019 and its operations are now consolidated under BMS. No public developer API has been identified; engagement is organized through BMS clinical trials, study connect, and investigator-sponsored research portals.

Celgene is profiled on the APIs.io network. Tagged areas include Biopharmaceutical, Clinical Trials, Oncology, Pharma, and Fortune 500.

🌐 Visit website 📡 Source on GitHub

8.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

BiopharmaceuticalClinical TrialsOncologyPharmaFortune 500

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.3/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/celgene: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Celgene Domain Security

DMARC

SECURITY

Press 5

Recent news and press coverage referencing this provider.

Get Started 1

Portal, sign-up, and the first successful call

Clinical Trials

Clinical Trials

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

LinkedIn

Website

Website

Other 3

Properties that don't map to a standard resource type

Parent Company

Parent Company

Study Connect

Study Connect

Research Pipeline

Research Pipeline

Source (apis.yml)

aid: celgene
url: https://raw.githubusercontent.com/api-evangelist/celgene/refs/heads/main/apis.yml
name: Celgene
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/celgene.png
tags:
- Biopharmaceutical
- Clinical Trials
- Oncology
- Pharma
- Fortune 500
created: '2024-01-15'
modified: '2026-04-23'
specificationVersion: '0.19'
description: Celgene Corporation was a global biopharmaceutical company focused on the discovery, development, and commercialization
  of innovative therapies for cancer and immune-inflammatory diseases. Celgene was acquired by Bristol Myers Squibb (BMS)
  in November 2019 and its operations are now consolidated under BMS. No public developer API has been identified; engagement
  is organized through BMS clinical trials, study connect, and investigator-sponsored research portals.
apis: []
common:
- type: DomainSecurity
  url: security/celgene-domain-security.yml
- type: GitHubOrganization
  url: https://github.com/celgene-research
- type: LinkedIn
  url: https://www.linkedin.com/company/celgene
- type: Website
  url: https://www.celgene.com
- type: Parent Company
  url: https://www.bms.com
- type: Clinical Trials
  url: https://www.bmsclinicaltrials.com/
- type: Study Connect
  url: https://www.bmsstudyconnect.com/
- type: Research Pipeline
  url: https://www.bms.com/researchers-and-partners/in-the-pipeline.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com

Celgene

Kin Score

Security Posture 1

Celgene Domain Security

Press 5

Celgene to use Exscientia's AI platform in effort ...

Exscientia announces multi-target, AI-driven drug ...

Exscientia announces new AI pharma collaboration

Celgene and Evotec's partner Exscientia enter 3-year AI ...

Exscientia Raises US$26 Million in Series B Financing ...

Resources